| Name | Title | Contact Details |
|---|---|---|
Mark Davin |
Vice President Corporate Finance | Profile |
Taylor Buff |
Director of Procurement- Americas Region | Profile |
Richard Rosik |
Director of Sales | Profile |
Josh Lumley |
Director, Finance Systems and Process | Profile |
Meghan Remmert |
VP of Finance, RSL | Profile |
SkylineDx is a pioneer in the field of molecular diagnostics through developing and commercializing innovative, signature-based diagnostics with a high clinical value that help to provide physicians and patients with the best individual care possible. At SkylineDx we transform life sciences into the daily practice of clinical diagnostics. We enable patients to benefit sooner and safer from new insights in the molecular basis of disease. We can truly make a difference by making our love of life tangible as state-of-the-art diagnostic products with a high clinical value. Our products are designed to support clinicians in making the right choices for their patients. This provides a unique and very real difference. Obvious perhaps, but never taken for granted here at SkylineDx.
Aeris Therapeutics Inc is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioVeris Corporation (BioVeris) is a global healthcare and biosecurity company developing technologies in diagnostics and vaccinology. It develops, manufactures and markets its M-SERIES family of products, which can serve as a platform for diagnostic
Prescott Medical Communications Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prothena Corporation plc (Nasdaq: PRTA) Prothena is a global biotechnology company seeking to fundamentally alter the course of progressive diseases. We are a late-stage clinical company focused on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. Our team has a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. Prothena`s pipeline focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins and our antibody-based product candidates target a number of potential indications, including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), ATTR amyloidosis (PRX004), and novel cell adhesion targets involved in psoriasis, psoriatic arthritis and other inflammatory diseases (PRX003). Prior to December 2012, Prothena’s business operated as part of Elan Corporation, plc. Prothena’s business consists of a substantial portion of Elan’s former drug discovery business platform. After the separation from Elan and the related distribution of our ordinary shares to Elan’s stockholders, our ordinary shares began trading on The Nasdaq Global Market under the symbol “PRTA” on December 21, 2012.